Skip to content

Abstract B133: ROCK2 inhibition alters pancreatic cancer fibrosis and decreases metastasis

Sep 2026 · Cancer Research · 0 citations

TL;DR

In patient derived models of pancreatic cancer, it is demonstrated that priming with KD025 disrupts the extracellular matrix whilst also reducing overall metastatic spreading and burden in this disease.

Abstract

Pancreatic cancer (PC) is a genetically complex, highly fibrotic, and treatment-refractory malignancy. At the time of clinical diagnosis most patients present with locally advanced, or metastatic disease, which renders them ineligible for surgery and leaves standard-of-care chemotherapy as the predominant treatment. However, chemotherapy has been shown to lead to chemo-induced fibrosis. The dense, stiff, and fibrotic stroma is a well-known driver of PC progression, metastasis, and chemo-resistance. Subcutaneous studies of high/low fibrosis patient-derived tumors from the APGI/APMA cohorts, showed different sensitivities to Folfirinox, suggesting that less fibrosis could enhance response to chemotherapy. ROCK2 is a major driver of cancer fibrosis, which we could target using the novel, FDA-approved anti-fibrotic ROCK2 inhibitor, KD025 (Kadmon, USA). In patient derived models of pancreatic cancer, we demonstrate that priming with KD025 disrupts the extracellular matrix whilst also reducing overall metastatic spreading and burden in this disease. Parallel anchorage independent growth, fluid flow–induced shear stress assessment, patient-derived matrices, and personalized in vivo models allowed us to deconstruct how ROCK2 inhibition can reduce PC spread. Niamh EP. Mills, Kendelle J. Murphy, Lily M. Channon, Sophie McKay, Daniel A. Reed, Anna E. Howell, Cecilia R. Chambers, Max Nobis, Victoria Lee, Astrid Magenau, Janett Stoehr, Brooke A. Pereira, Anaiis Zaratzian, Michael Tayao, Andrew Da Silva, Ruth J. Lyons, Anthony K . Gill, Andrew V. Biankin, Lisa G. Horvath, Jennifer P. Morton, Tri G. Phan, Thomas R. Cox, Marina Pajic, David Herrmann, Paul Timpson, Elizabeth Caldon. ROCK2 inhibition alters pancreatic cancer fibrosis and decreases metastasis [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B133.

View source

Similar papers

Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Sep 2026

Abstract A056: Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...

Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al. · 0 citations
Sep 2026

Abstract B124: Targeting the tumor microenvironment: A novel therapeutic strategy for pancreatic ductal adenocarcinoma

Therapeutic N-glycan modulation is highlighted as a promising tumor microenvironment–targeted strategy for PDAC treatment by disrupting tumor–stroma communication and remodeling the tumor microenvironment by disrupting tumor–stroma communication and remodeling the tumor microenvironment.

Hui-Lan Chang, Chin-Chun Chang, Gita Riswana Nawung Rida et al. · 0 citations
Sep 2026

Abstract A011: Targeting tumor-associated macrophage vulnerabilities to enhance therapy in pancreatic cancer

PDAC chemotherapy, including standard-of-care gemcitabine (GEM)/nab-paclitaxel (NP) regimen, is associated with the accumulation of TAMs that are functionally linked to therapeutic resistance and worse prognosis. GEM, but not NP, drives TAM polarization toward an immunosuppressive, M2-like phenotype characterized...

M. Romano, Makenna May, L. Pike et al. · 0 citations
Open access Sep 2026

Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodeling of the extracellular matrix

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that accounts for nearly 20% of breast cancer diagnoses. Despite recent approvals of novel therapeutic agents for TNBC, neoadjuvant chemotherapy remains part of standard of care treatment for TNBC patients. However, approximately 60% of TNBC...

Anna Yui, Liang-Ying Peng, Katherine C. Lew et al. · 0 citations
Clinical trial Open access Nov 2026

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients

BACKGROUND TGF-β drives fibroblast activation in cancer and is a resistance biomarker to PD-1/PD-L1 blockade. METHODS Focusing on the tumor stroma, we characterized the impact of neoadjuvant treatment with bintrafusp alfa (BA), a dual PD-L1 and TGF-β inhibitor, in a window-of-opportunity study with 6 patients with head...

Caroline Hoffmann, Jan-Timon Werle, P. Sirven et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.